close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

19.73 -0.37 (-1.84%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
19 20 Next >
News headline image
Why BYND Cannasoft Enterprises Shares Are Trading Lower By 40%; Here Are 20 Stocks Moving Premarket ↗
Gainers 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
It's time to start off the trading week with a breakdown of all the biggest pre-market stock movers worth watching on Monday! 
Via InvestorPlace
News headline image
Apellis Announces Seven Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
The Latest Analyst Ratings for Apellis Pharmaceuticals ↗
 
Via Benzinga
Apellis Pharmaceuticals Inc. (NASDAQ: APLS) is a Stock Spotlight on 5/25
Via Investor Brand Network
News headline image
Needham Maintains Buy Rating for Apellis Pharmaceuticals: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Top-Notch Biotech Apellis Soars After New Drug Obliterates Sales Views ↗
The company easily beat sales calls on the back of Syfovre, a geography atrophy drug. 
Via Investor's Business Daily
News headline image
The Latest Analyst Ratings for Apellis Pharmaceuticals ↗
 
Via Benzinga
News headline image
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree ↗
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
News headline image
Apellis Pharma Flunks On Primary, Secondary Endpoints In Amyotrophic Lateral Sclerosis Study ↗
 
Via Benzinga
News headline image
Why Shares of Annexon Are Plummeting Thursday ↗
Mixed trial results on a geographic atrophy eye drug led investors to sell the biotech stock. 
Via The Motley Fool
News headline image
Apellis Reports Top-Line Results from Phase 2 MERIDIAN Study in ALS
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
Earnings Preview: Apellis Pharmaceuticals ↗
 
Via Benzinga
News headline image
Why These 3 Nasdaq Stocks Buckled Today ↗
The FTC's decision to sue to block a high-profile merger is weighing on biotech valuations today. 
Via The Motley Fool
News headline image
Are Small Caps a Harbinger of Market Declines?
The iShares Russell 2000 ETF outperformed the S&P 500 last week, but that may be short-lived. Small-cap momentum is often a bellwether for broad-market action. 
Via MarketBeat
Topics ETFs Stocks
News headline image
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharma's Newly Approved Drug Exceeds Sales Projections, Bullish Analyst Raises Expectations ↗
Apellis Pharmaceuticals Inc (NASDAQ: APLS) reported Q1 revenues of $44.8 million, surpassing the consensus of $26.10 million and  
Via Benzinga
News headline image
Apellis Pharmaceuticals Reports First Quarter 2023 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals to Present at the Bank of America Securities 2023 Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today ↗
These three biotech stocks were on the volatile side today. 
Via The Motley Fool
News headline image
Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma ↗
The company is working on a treatment for the eye disease known as geographic atrophy. 
Via Investor's Business Daily
News headline image
Top 5 Health Care Stocks That Could Sink Your Portfolio This Quarter ↗
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
News headline image
Apellis Pharmaceuticals to Host Conference Call on May 4, 2023, to Discuss First Quarter 2023 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Apellis Presents Phase 3 Functional Analyses of SYFOVRE™ (pegcetacoplan injection) for Geographic Atrophy
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Announces Validation of Four Marketing Applications for Pegcetacoplan for Geographic Atrophy
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today